Trial Profile
A phase I study of OCID 2987 for the treatment of inflammatory disorders including chronic obstructive pulmonary disease (COPD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2014
Price :
$35
*
At a glance
- Drugs OCID 2987 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- 19 Dec 2014 New trial record